Table 3. Patient demographics and baseline characteristics.

Age	Gender	ECOG PS	Histology	Criteria for study participation	Number of prior 131 therapies.*	Prior Cumulative I131 dose	Time since last I131 therapy (Months)	Times since diagnosis of metastatic disease (months)	Metastatic sites	PFS
72	Male	0	Follicular	3	3	930	23	78	Lung, Bone	107
37	Female	0	Papillary arising in a Struma ovarii	4	3	757	14	50	Liver, retroperitoneal lymphadenopathy	147
58	Male	0	Papillary-follicular	4	2	290	6	18	Bone	433
54	Male	0	Papillary	3	1	154	49	49	Lung, bone	202
65	Female	1	Papillary	1,2	1	158	5	5	Lung	548
59	Male	1	Papillary	1	2	Unknown	80	80	Bone, Mediastinal mass	253

*. Criteria to participate in the study 1) One or more measurable lesions with low or absent ¹³¹I uptake on the most recent pre-study radioiodine scans. 2) Disease progression according to RECIST criteria in imaging studies within 12 months of ¹³¹I therapy despite ¹³¹I uptake on RAI scan. 3) >50% increase in suppressed thyroglobulin levels during 12 months of I-131 therapy despite ¹³¹I uptake on RAI scan). 4) Evidence of at least one site of known disease with preserved ¹³¹I uptake above background levels on a diagnostic post-therapy ¹³¹I scan prior to study entry.